ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

esmo.org

PRECEPTORSHIP PROGRAMME

Non-Small-Cell Lung Cancer (NSCLC)

Standards of care, evolving paradigm and future perspectives

SINGAPORE

21-22 NOVEMBER 2018

Co-Chairs Jean-Yves Douillard, CH
Ross A. Soo, SG

ESMO PRECEPTORSHIP PROGRAMME
NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

Singapore
21-22 November 2018

CO-CHAIRS:

Jean-Yves Douillard, Switzerland
Ross A. Soo, Singapore

SPEAKERS:

Byoung Chul Cho, South Korea
Simon Ekman, Sweden
Steven C.-H. Kao, Australia
Keith M. Kerr, United Kingdom
Pyng Lee, Singapore
Tetsuya Mitsudomi, Japan
Tony S. K. Mok, Hong Kong
Silvia Novello, Italy
Suresh Senan, Netherlands
Masahiro Tsuboi, Japan

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology and histoprognostic factors in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

MSD

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: **courses@esmo.org**
www.esmo.org

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

Wednesday, 21 November 2018

13:00-14:00	**Lunch**	
14:00-14:10 **10'**	**Opening and welcome**	
10'	Welcome from ESMO, objectives and scientific introduction	Jean-Yves Douillard, CH
14:10-15:50 **100'**	**SESSION 1** **Screening, diagnosis and staging**	**Chair:** **Simon Ekman, SE**
30'	Lung cancer screening: Current data and screening in the Asian setting	Pyng Lee, SG
30'	Lung cancer diagnosis: Role of pathology and genetic analysis	Keith M. Kerr, UK
30'	Lung cancer: What's next after diagnosis?	Silvia Novello, IT
10'	Discussion	Faculty
15:50-16:20	**Coffee break**	
16:20-17:20 **60'**	**SESSION 2** **Audience cases**	**Chairs: Jean-Yves Douillard, CH** **Ross A. Soo, SG**
60'	Participants clinical case discussion (3x20')	Faculty
20:00	**Dinner**	

Thursday, 22 November 2018

09:00-10:40 **100'**	**SESSION 3** **Multi-disciplinary lung tumour board**	**Chair:** **Ross A. Soo, SG**
50'	Management of stage III - Case presentation - Radiotherapist's point of view - Medical oncologist's point of view - Surgeon's point of view - Discussion	Suresh Senan, NL Simon Ekman, SE Masahiro Tsuboi, JP
50'	Management of oligometastatic disease - Case presentation - Radiotherapist's point of view - Medical oncologist's point of view - Surgeon's point of view - Discussion	Suresh Senan, NL Simon Ekman, SE Masahiro Tsuboi, JP
10:40-11:10	**Coffee break**	
11:10-12:20 **70'**	**SESSION 4** **Systemic therapy for advanced NSCLC**	**Chair:** **Tetsuya Mitsudomi, JP**
30'	Systemic therapy for non-oncogene addicted NSCLC	Ross A. Soo, SG
30'	Immune Checkpoint Inhibitors	Silvia Novello, IT
10'	Discussion	Faculty
12:20-13:20	**Lunch**	

13:20-15:30 130’	**SESSION 5** **Targeted therapies / other thoracic tumours**	**Chair:** **Tetsuya Mitsudomi, JP**
30’	EGFR+ in 1L: Resistance, sequencing	Tetsuya Mitsudomi, JP
30’	ALK+ in 1L: Resistance, sequencing	Tony S. K. Mok, HK
30’	Targeted therapy beyond EGFR/ALK (BRAF, ROS1, RET, MET, NTRK)	Byoung Chul Cho, KR
30’	Updates in malignant mesothelioma and SCLC	Steven C.-H. Kao, AU
10’	Discussion	Faculty
15:30-16:00	Coffee break	
16:00-17:00 **60’**	**SESSION 6** **Audience cases**	**Chairs: Jean-Yves Douillard, CH** **Ross A. Soo, SG**
60’	Participants clinical case discussion (3x20’)	Faculty
17:00-17:15 **15’**	**Conclusion and take home messages**	**Ross A. Soo, SG**

Note: Each 20 minute slot for clinical case discussion includes 10’ case presentation and 10’ Q&A / panel discussion